BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

...Xu will join the board, along with Rodney Lappe, who was SVP, CSO at the CovX...
BioCentury | Jul 1, 2013
Company News

PeptiDream, Pfizer deal

...closed its CovX research unit. The pharma acquired CovX Pharmaceuticals Inc. in 2007 for the CovX...
BioCentury | Jun 27, 2013
Company News

PeptiDream slides on end of Pfizer deal

...closed its CovX research unit. The pharma acquired CovX Pharmaceuticals Inc. in 2007 for the CovX...
BioCentury | Jun 11, 2013
Politics & Policy

Sauer joins C-Path

...Consortium (PSTC). Sauer previously was senior director of in vitro pharmacology and DMPK at Pfizer's CovX...
BioCentury | Apr 22, 2013
Company News

Lpath management update

...Gary Woodnutt as SVP of research, formerly VP of open innovation at Pfizer Inc. 's CovX...
BioCentury | Mar 4, 2013
Company News

Pfizer antibodies news

...Pfizer said it closed its CovX research unit in San Diego, Calif., which housed "just under"...
...Diego, Calif., which housed "just under" 100 employees. The pharma said it is reviewing the CovX...
...the transition, but did not disclose details. Pfizer acquired CovX in 2008 for undisclosed terms. CovX...
BioCentury | Jun 4, 2012
Clinical News

CVX-060: Phase Ib/II data

...York, N.Y. Product: CVX-060 Business: Cancer Molecular target: Angiopoietin 2 (ANG2) (ANGPT2) Description: Humanized monoclonal CovX-Body...
BioCentury | Jan 6, 2011
Distillery Techniques

Technology: Drug platforms

...modified to bind two different protein targets (bispecific CovX-Bodies) could help treat cancer. The bispecific CovX-Bodies...
...target-specific peptides, each linked to one of the antibody's binding regions. In vitro, a bispecific CovX-Body...
...growth compared with monospecific CovX-Bodies targeting only VEGF or ANG2. CVX-241 (PF-05057459) from Pfizer Inc.'s CovX Research LLC...
BioCentury | May 4, 2009
Company News

Pfizer management update

...of Pfizer's Biotherapeutics and Bioinnovation Center, effective May 31; Rodney Lappe, CSO of the center's CovX Research LLC...
BioCentury | Apr 29, 2009
Company News

Goodman leaving Pfizer

...Biotherapeutics and Bioinnovation Center, effective May 31. Rodney Lappe, who is CSO of the center's CovX Research LLC...
Items per page:
1 - 10 of 27
BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

...Xu will join the board, along with Rodney Lappe, who was SVP, CSO at the CovX...
BioCentury | Jul 1, 2013
Company News

PeptiDream, Pfizer deal

...closed its CovX research unit. The pharma acquired CovX Pharmaceuticals Inc. in 2007 for the CovX...
BioCentury | Jun 27, 2013
Company News

PeptiDream slides on end of Pfizer deal

...closed its CovX research unit. The pharma acquired CovX Pharmaceuticals Inc. in 2007 for the CovX...
BioCentury | Jun 11, 2013
Politics & Policy

Sauer joins C-Path

...Consortium (PSTC). Sauer previously was senior director of in vitro pharmacology and DMPK at Pfizer's CovX...
BioCentury | Apr 22, 2013
Company News

Lpath management update

...Gary Woodnutt as SVP of research, formerly VP of open innovation at Pfizer Inc. 's CovX...
BioCentury | Mar 4, 2013
Company News

Pfizer antibodies news

...Pfizer said it closed its CovX research unit in San Diego, Calif., which housed "just under"...
...Diego, Calif., which housed "just under" 100 employees. The pharma said it is reviewing the CovX...
...the transition, but did not disclose details. Pfizer acquired CovX in 2008 for undisclosed terms. CovX...
BioCentury | Jun 4, 2012
Clinical News

CVX-060: Phase Ib/II data

...York, N.Y. Product: CVX-060 Business: Cancer Molecular target: Angiopoietin 2 (ANG2) (ANGPT2) Description: Humanized monoclonal CovX-Body...
BioCentury | Jan 6, 2011
Distillery Techniques

Technology: Drug platforms

...modified to bind two different protein targets (bispecific CovX-Bodies) could help treat cancer. The bispecific CovX-Bodies...
...target-specific peptides, each linked to one of the antibody's binding regions. In vitro, a bispecific CovX-Body...
...growth compared with monospecific CovX-Bodies targeting only VEGF or ANG2. CVX-241 (PF-05057459) from Pfizer Inc.'s CovX Research LLC...
BioCentury | May 4, 2009
Company News

Pfizer management update

...of Pfizer's Biotherapeutics and Bioinnovation Center, effective May 31; Rodney Lappe, CSO of the center's CovX Research LLC...
BioCentury | Apr 29, 2009
Company News

Goodman leaving Pfizer

...Biotherapeutics and Bioinnovation Center, effective May 31. Rodney Lappe, who is CSO of the center's CovX Research LLC...
Items per page:
1 - 10 of 27